These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 20228675)

  • 1. Cinacalcet for the treatment of primary hyperparathyroidism.
    Dillon ML; Frazee LA
    Am J Ther; 2011 Jul; 18(4):313-22. PubMed ID: 20228675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical management of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop.
    Khan A; Grey A; Shoback D
    J Clin Endocrinol Metab; 2009 Feb; 94(2):373-81. PubMed ID: 19193912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of cinacalcet hydrochloride in clinical management of primary hyperparathyroidism in multiple endocrine neoplasia type 1.
    Del Prete M; Marotta V; Ramundo V; Marciello F; Di Sarno A; Esposito R; Carratù AC; De Luca Di Roseto C; Di Somma C; Colao A; Faggiano A
    Minerva Endocrinol; 2013 Dec; 38(4):389-94. PubMed ID: 24285106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of skeletal health in patients with asymptomatic primary hyperparathyroidism.
    Lewiecki EM
    J Clin Densitom; 2010; 13(4):324-34. PubMed ID: 21029971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cinacalcet (Sensipar) provides no measurable clinical benefits for patients with primary hyperparathyroidism and may accelerate bone loss with prolonged use.
    Norman J; Lopez J; Politz D
    Ann Surg Oncol; 2012 May; 19(5):1466-71. PubMed ID: 21922336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonsurgical management of mild primary hyperparathyroidism - a reasonable option.
    Grey A
    Clin Endocrinol (Oxf); 2012 Nov; 77(5):639-44. PubMed ID: 22803518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcimimetics versus parathyroidectomy for treatment of primary hyperparathyroidism: retrospective chart analysis of a prospective database.
    Keutgen XM; Buitrago D; Filicori F; Kundel A; Elemento O; Fahey TJ; Zarnegar R
    Ann Surg; 2012 May; 255(5):981-5. PubMed ID: 22470074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical management of primary hyperparathyroidism.
    Khan AA
    J Clin Densitom; 2013; 16(1):60-3. PubMed ID: 23374743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Nephrolithiasis associated with normocalcemic or hypercalcemic primary hyperparathyroidism: focus on calciomimetics].
    Brardi S; Ponchietti R; Duranti E
    G Ital Nefrol; 2016; 33(6):. PubMed ID: 28134399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New strategies for the treatment of hyperparathyroidism incorporating calcimimetics.
    de Francisco AL
    Expert Opin Pharmacother; 2008 Apr; 9(5):795-811. PubMed ID: 18345956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cinacalcet as alternative treatment for primary hyperparathyroidism: achievements and prospects.
    Duntas LH; Stathatos N
    Endocrine; 2011 Jun; 39(3):199-204. PubMed ID: 21442382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Medical treatment of primary hyperparathyroidism: role of calcimimetics].
    Muñoz Torres M; García Martín A
    Endocrinol Nutr; 2009 Apr; 56 Suppl 1():29-34. PubMed ID: 19627758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transient hypercortisolism and symptomatic hyperthyroidism associated to primary hyperparathyroidism in an elderly patient: case report and literature review.
    Sabbadin C; Donà G; Bordin L; Iacobone M; Camozzi V; Mian C; Armanini D
    BMC Endocr Disord; 2015 Jan; 15():4. PubMed ID: 25631825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism.
    Dong BJ
    Clin Ther; 2005 Nov; 27(11):1725-51. PubMed ID: 16368445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic challenges in elderly patients with symptomatic hypercalcaemia caused by primary hyperparathyroidism.
    Jacobs L; Samson MM; Verhaar HJ; Koek HL
    Neth J Med; 2012 Jan; 70(1):35-8. PubMed ID: 22271812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Asymptomatic primary hyperparathyroidism: surgical and medical management.
    Francucci CM; Ceccoli L; Caudarella R; Rilli S; Vescini F; Boscaro M
    J Endocrinol Invest; 2011 Jul; 34(7 Suppl):50-4. PubMed ID: 21985981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cinacalcet hydrochloride for the treatment of hyperparathyroidism.
    Verheyen N; Pilz S; Eller K; Kienreich K; Fahrleitner-Pammer A; Pieske B; Ritz E; Tomaschitz A
    Expert Opin Pharmacother; 2013 Apr; 14(6):793-806. PubMed ID: 23452174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cinacalcet HCl suppresses Cyclin D1 oncogene-derived parathyroid cell proliferation in a murine model for primary hyperparathyroidism.
    Imanishi Y; Kawata T; Kenko T; Wada M; Nagano N; Miki T; Arnold A; Inaba M
    Calcif Tissue Int; 2011 Jul; 89(1):29-35. PubMed ID: 21541686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity.
    Peacock M; Bilezikian JP; Bolognese MA; Borofsky M; Scumpia S; Sterling LR; Cheng S; Shoback D
    J Clin Endocrinol Metab; 2011 Jan; 96(1):E9-18. PubMed ID: 20943783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MEN1-related hyperparathyroidism: response to cinacalcet and its relationship with the calcium-sensing receptor gene variant Arg990Gly.
    Filopanti M; Verga U; Ermetici F; Olgiati L; Eller-Vainicher C; Corbetta S; Persani L; Beck-Peccoz P; Spada A
    Eur J Endocrinol; 2012 Aug; 167(2):157-64. PubMed ID: 22577108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.